Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the efficacy of SAIT101 with rituximab (MabThera®) when administered as a first-line immunotherapy in patients with low tumor burden follicular lymphoma (LTBFL).
Critère d'inclusion
- Low Tumor Burden Follicular Lymphoma (LTBFL)